Growing knowledge of the control of glucose metabolism permits the testing of alternative treatments to insulin to maintain euglycemia. Diminishing glucagon action on the liver (1) and increasing leptin (2) are prime examples of promising peptide hormone treatments that could be useful in glucose regulation. A report from Morton and colleagues (3) in this issue provides data that a systems biology model could integrate these two points of view of glucose regulation.

Brain-derived neurotrophic factor (BDNF) and its cognate receptor TrkB are involved in the regulation of energy balance and glucose homeostasis via its effects in the central nervous system. Perturbed BDNF signaling in the brain triggers hyperphagia and obesity in mice, suggesting that BDNF acts as an anorexigenic signaling molecule (46). However, the cellular mechanisms underlying the anorexigenic effects of BDNF have not been clearly defined. As a neurotrophic factor, BDNF promotes survival, induces differentiation of neurons in the developing and adult central nervous system (7), and forms appropriate synaptic connections at central synapses (8). Thus, the obesity phenotype observed in BDNF- and TrkB-mutant animals can be, in part, due to neurodevelopmental anomalies (6,911).

In addition to neurotrophic functions of BDNF, BDNF has acute and nonneurotrophic effects on body weight and food intake. Hypothalamic infusions of BDNF alter eating behavior and attenuate obesity in BDNF heterozygous mutant mice (9). Central administration of a TrkB agonist reduces food intake and body weight in mice (12). Furthermore, systemic BDNF administration improves glucose tolerance in diet-induced obesity and diabetic mice (13), as well as in db/db animals (14). Thus, it is likely that BDNF alters feeding-related neuronal activity, which in turn regulates energy homeostasis.

The ventromedial nucleus of the hypothalamus (VMH) attracted major attention as early lesion studies of the VMH induced hyperphagia and obesity in a variety of species, including humans (rev. in 15). BDNF is expressed at high levels in this nucleus, and its expression in the VMH is regulated by nutrients and nutrient-related signal molecules, including glucose, leptin, and melanocortins (5,6,16). Moreover, a recent study (17) demonstrated that a subset of steroidogenic factor-1 (SF-1) neurons in the VMH synthesize and release BDNF in an activity-dependent manner. Endogenous and exogenous BDNF attenuates gamma-aminobutyric acid (GABAergic) inhibitory tone onto SF-1 neurons, suggesting that the electrophysiological action of BDNF on synaptic activity in the VMH may play a role in regulating overall energy homeostasis. In this issue, Morton and colleagues provide direct physiological evidence that the VMH is the target for BDNF action on blood glucose levels in an animal model of uncontrolled insulin-deficient diabetes. In this study, the authors demonstrate that central injection of BDNF lowers blood glucose levels and that this effect is independent of insulin since streptozotocin-diabetic animals show severe insulin deficiency. Alternatively, BDNF reduces hepatic glucose production through inhibition of the key gluconeogenic enzymes, including glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, which are elevated in streptozotocin-diabetic animals. The authors further show that microinjection of BDNF into the VMH lowers fasting blood glucose levels without changing energy intake. This is in contrast with the fact that lowering glucose levels induced by intracerebroventricular administration of BDNF is associated with reduced food intake, suggesting that BDNF also acts outside the VMH. Interestingly, intracerebroventricular injection of BDNF does not improve glucose uptake in skeletal muscle and brown adipose tissue in streptozotocin-diabetic animals.

In fact, the identity of TrkB-expressing hypothalamic and/or extrahypothalamic neurons remains to be determined. BDNF induced Finkel-Biskis-Jinkins osteogenic sarcoma (FOS) expression in the paraventricular nucleus (PVN), dorsomedial nucleus (DMH), and VMH (5). Moreover, the VMH sends projections to the PVN and DMH (18). It is plausible that disinhibition of VMH SF-1 neurons by BDNF (17) increases the excitability of PVN and DMH neurons and then subsequently alters glucagon secretion and liver glucose production. Interestingly, although TrkB-expressing neurons are found in the arcuate and lateral hypothalamus, it appears that few neurons in these nuclei, including orexin, melanin-concentrating hormone, cocaine- and amphetamine-regulated transcript, and neuropeptide Y neurons, express TrkB (6). It should also be noted that not only VMH neurons respond to BDNF but also a subset of VMH neurons synthesize and release BDNF (17). Thus, the regulation of BDNF-expressing neurons in the VMH will be critical in maintaining blood glucose levels in normal and diabetic conditions.

The current report by Morton and colleagues (3) builds upon the group’s previous work with leptin’s effect on diabetic rats (19) with the clear anticipation that BDNF is a mediator of leptin. With a clear glucose lowering effect in insulin-deficient rats, leptin caused an increase in peripheral glucose uptake as well as a decrease in hepatic glucose production. This is the major difference between leptin and BDNF, which only reduced liver glucose output, indicating that leptin has other significant mediators that act independently of BDNF.

Although previous studies, including the present work of Morton and colleagues, suggest that the nonneurotrophic actions of BDNF regulate blood glucose levels, the neurotrophic role of BDNF may also play a role in maintaining overall energy balance, including glucose homeostasis (20,21). In summary, one would predict that the ability of leptin to control glucose is dependent upon decreasing hepatic glucose output, mediated by BDNF and partially dependent upon decreasing glucagon secretion as well by increasing peripheral glucose uptake that is independent of BDNF.

See accompanying brief report, p. 1512.

The authors are supported by the grants DK092246 (Y.-H.J.), DK026687 (S.C.C.), and HD058155 (S.C.C.).

No potential conflicts of interest relevant to this article were reported.

1.
Unger
RH
,
Cherrington
AD
.
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
.
J Clin Invest
2012
;
122
:
4
12
[PubMed]
2.
Morton
GJ
,
Schwartz
MW
.
Leptin and the central nervous system control of glucose metabolism
.
Physiol Rev
2011
;
91
:
389
411
[PubMed]
3.
Meek TH, Wisse BE, Thaler JP, et al. BDNF action in the brain attenuates diabetic hyperglycemia via insulin-independent inhibition of hepatic glucose production. Diabetes 2013;62:
1512
1518
4.
Rios
M
,
Fan
G
,
Fekete
C
, et al
.
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity
.
Mol Endocrinol
2001
;
15
:
1748
1757
[PubMed]
5.
Unger
TJ
,
Calderon
GA
,
Bradley
LC
,
Sena-Esteves
M
,
Rios
M
.
Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity
.
J Neurosci
2007
;
27
:
14265
14274
[PubMed]
6.
Xu
B
,
Goulding
EH
,
Zang
K
, et al
.
Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor
.
Nat Neurosci
2003
;
6
:
736
742
[PubMed]
7.
Lipsky
RH
,
Marini
AM
.
Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity
.
Ann N Y Acad Sci
2007
;
1122
:
130
143
[PubMed]
8.
Cohen-Cory
S
,
Kidane
AH
,
Shirkey
NJ
,
Marshak
S
.
Brain-derived neurotrophic factor and the development of structural neuronal connectivity
.
Dev Neurobiol
2010
;
70
:
271
288
[PubMed]
9.
Kernie
SG
,
Liebl
DJ
,
Parada
LF
.
BDNF regulates eating behavior and locomotor activity in mice
.
EMBO J
2000
;
19
:
1290
1300
[PubMed]
10.
Lyons
WE
,
Mamounas
LA
,
Ricaurte
GA
, et al
.
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities
.
Proc Natl Acad Sci USA
1999
;
96
:
15239
15244
[PubMed]
11.
Fox
EA
,
Byerly
MS
.
A mechanism underlying mature-onset obesity: evidence from the hyperphagic phenotype of brain-derived neurotrophic factor mutants
.
Am J Physiol Regul Integr Comp Physiol
2004
;
286
:
R994
R1004
[PubMed]
12.
Tsao
D
,
Thomsen
HK
,
Chou
J
, et al
.
TrkB agonists ameliorate obesity and associated metabolic conditions in mice
.
Endocrinology
2008
;
149
:
1038
1048
[PubMed]
13.
Nakagawa
T
,
Ogawa
Y
,
Ebihara
K
, et al
.
Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance
.
Int J Obes Relat Metab Disord
2003
;
27
:
557
565
[PubMed]
14.
Tonra
JR
,
Ono
M
,
Liu
X
, et al
.
Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice
.
Diabetes
1999
;
48
:
588
594
[PubMed]
15.
King
BM
.
The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight
.
Physiol Behav
2006
;
87
:
221
244
[PubMed]
16.
Komori
T
,
Morikawa
Y
,
Nanjo
K
,
Senba
E
.
Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus
.
Neuroscience
2006
;
139
:
1107
1115
[PubMed]
17.
Jo
YH
.
Endogenous BDNF regulates inhibitory synaptic transmission in the ventromedial nucleus of the hypothalamus
.
J Neurophysiol
2012
;
107
:
42
49
[PubMed]
18.
Tran
PV
,
Lee
MB
,
Marín
O
, et al
.
Requirement of the orphan nuclear receptor SF-1 in terminal differentiation of ventromedial hypothalamic neurons
.
Mol Cell Neurosci
2003
;
22
:
441
453
[PubMed]
19.
German
JP
,
Thaler
JP
,
Wisse
BE
, et al
.
Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia
.
Endocrinology
2011
;
152
:
394
404
[PubMed]
20.
Lee
DA
,
Bedont
JL
,
Pak
T
, et al
.
Tanycytes of the hypothalamic median eminence form a diet-responsive neurogenic niche
.
Nat Neurosci
2012
;
15
:
700
702
[PubMed]
21.
McNay
DE
,
Briançon
N
,
Kokoeva
MV
,
Maratos-Flier
E
,
Flier
JS
.
Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice
.
J Clin Invest
2012
;
122
:
142
152
[PubMed]
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.